Charcot-Marie-Tooth Disease Market to Surpass US$ 3459.1 Million by 2028

Global Charcot-Marie-Tooth Disease Market, by Disease Type (CMT 1, CMT 2, CMT 3, and Others), by Drug Type (Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics and Pipeline Drug), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America),  was valued at US$ 793.9 Million in 2021 and is projected to exhibit a CAGR of 23.4% during the forecast period (2021-2028).

The key market players are focusing on the introduction of novel therapies for the treatment of charcot-marie-tooth disease, which is projected to provide a profitable opportunity for industry participants to introduce their novel products. For instance, Pharnext, an advanced clinical-stage biopharmaceutical company, provided data on its novel product PXT3003. PXT3003 is a new type of synergistic fixed-dose combination of baclofen, naltrexone, and sorbitol, administered as an oral solution twice a day. The three individual components of PXT3003 were selected to down-regulate the overexpression of PMP22 protein, thereby improving neuronal signals in dysfunctional peripheral nerves, which is a component of the pathophysiology of the disease. PXT3003 has shown promising and consistent results in phase II and phase III preclinical and clinical studies.           

Global Charcot-Marie-Tooth Disease Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 pandemic has affected various industries globally. The players operating in the global charcot-marie-tooth disease market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of September 24, 2021, are approximately 230,418,451 confirmed cases with 4,724,876 deaths.

The coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of CMT disease manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. Moreover, the supply and production of pharmaceutical products is also affected due to lockdown imposed globally during the COVID-19 pandemic. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products.

Browse 35 Market Data Tables and 34 Figures spread through 189 Pages and in-depth TOC on “Global Charcot-Marie-Tooth Disease Market”-  Forecast to 2028,  Global Charcot-Marie-Tooth Disease Market, by Disease Type (CMT 1, CMT 2, CMT 3, and Others), by Drug Type (Nonsteroidal anti-inflammatory drugs, Cyclooxygenase-2 inhibitors, Tricyclic antidepressants, Anticonvulsants, Analgesics and Pipeline Drug), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/charcot-marie-tooth-disease-market-4698

The key players operating in the global charcot-marie-tooth disease market are focusing on adoption of inorganic growth strategies such as acquisition and collaboration to increase their market presence in the global market. For instance, in September 2020, Pharnext SA  announced a research collaboration with the Charcot-Marie-Tooth Association (CMTA) patient advocacy group in the U.S. to investigate new biomarkers associated with charcot-marie-tooth disease type 1A (CMT1A), the subtype most common disease.

Key Takeaways of the Global Charcot-Marie-Tooth Disease Market:

• The global charcot-marie-tooth disease market is expected to exhibit a CAGR of 23.4% during the forecast period, owing to the launch of observational study on CMT (Charcot-Marie-Tooth). For instance, on October 09, 2018, Digital healthcare company Vitaccess and Pharnext SA, a biopharmaceutical company developing a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, announced the launch of an international study on charcot-marie-tooth disease (CMT) with a custom digital application called CMT & Me.
• Among disease type, CMT1 is the most common type of CMT, accounting for about two-thirds of all cases globally. It is caused by genetic defects that damage the myelin sheath that lines the nerves, which is why it is commonly known as demyelinating CMT.
• Major players operating in the global charcot-marie-tooth disease market include Addex Therapeutics Ltd., Affectis Pharmaceuticals AG, Genzyme Corp, Lead Discovery Center GmbH, Pharnext SA, Acceleron Pharma, MedDay Pharmaceuticals, Bristol-Myers-Squibb Company, Inflectis Bio Science Health Company, Helixmith Co., Ltd., and Neurogene Inc.